Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
4(80.0%)
N/A
1(20.0%)
5Total
Phase 3(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06578572Phase 3Recruiting

Seasonal R21 Mass Vaccination for Malaria Elimination

Role: collaborator

NCT04053907Not ApplicableUnknown

P. Falciparum Infection Dynamics and Transmission to Inform Elimination

Role: collaborator

NCT03576313Phase 3Completed

Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination

Role: collaborator

NCT00118794Phase 3Completed

Lapdap and Coartemether for Uncomplicated Malaria

Role: collaborator

NCT00118807Phase 3Completed

Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children

Role: collaborator

All 5 trials loaded